Acme United Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACU research report →
Range $70 – $70
Price Chart
About the company
Acme United Corporation is a global supplier specializing in first aid, safety, cutting, sharpening, and measuring tools. Its products cater to a diverse clientele across educational institutions, households, corporate offices, hardware stores, sporting goods outlets, and industrial sectors throughout the United States, Canada, Europe, and other international markets. The company's extensive portfolio is distributed under several prominent brands.
- CEO
- Walter C. Johnsen
- IPO
- 1980
- Employees
- 649
- HQ
- Shelton, CT, US
Get TickerSpark's AI analysis on ACU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $262.55M
- P/E
- 22.70
- Fwd P/E
- 25.50
- PEG
- 1.74
- P/S
- 1.20
- P/B
- 2.10
- EV/EBITDA
- 14.24
- Div Yield
- 0.96%
- Gross Margin
- 41.68%
- Op Margin
- 7.23%
- Net Margin
- 5.15%
- ROE
- 9.45%
- ROIC
- 7.28%
Latest fiscal year · YoY change
- Revenue
- $196.54M+1.1%
- Gross Profit
- $77.41M+1.4%
- Op Income
- $14.72M
- Net Income
- $10.19M+1.6%
- EPS
- $2.69-0.7%
- OCF Growth
- +52.2%
- FCF Growth
- +57.0%
- 52W High
- $72.21
- 52W Low
- $35.61
- 50D MA
- $64.63
- 200D MA
- $52.12
- Beta
- 0.50
- RSI (14)
- 52
- Avg Volume
- 40.25K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Acme United posted strong Q3 growth, boosted by a tariff refund, My Medic contribution, and broad-based demand, while signaling a solid Q4 and continued momentum into 2027.· October 27, 2026
- Q3 net sales rose 18% to $58 million, with net income up 80% to $3.4 million and EPS up 74% to $0.80.
- A $6 million tariff refund lifted results; excluding the refund impact, net income still rose 24% to $2.4 million and EPS to $0.55.
- Gross margin expanded to 45.3% from 39.1%, helped by the tariff refund and favorable mix from higher-margin My Medic sales.
- U.S. sales increased 20%; Westcott and First Aid were strong, and back-to-school sell-through was described as excellent.
- Management expects a seasonally strong Q4, has already booked new 2027 business, and plans to close the Marlborough DMT plant in Q4 with over $1 million in annual savings starting in January 2027.
Net sales in the third quarter were $58 million, up 18% from $49.1 million a year ago. Net income was $3.4 million versus $1.9 million last year, up 80%, and diluted EPS was $0.80 versus $0.46, up 74%. Excluding the tariff refund-related benefit, net income was $2.4 million and EPS was $0.55, both up 24% and 20%, respectively, versus last year. Gross margin was 45.3% versus 39.1% in Q3 2025; for the first nine months, sales were $173 million, up 16%, gross margin was 42.6% versus 39.8%, and net income was $9.5 million versus $8.3 million. For Q4, management said the quarter is expected to be seasonally strong in both sales and earnings, and it is projecting a solid fourth quarter of 2026. The company also said it has already booked new business in First Aid and is seeing continued strength in cutting tools for 2027.
Walter Johnsen struck an upbeat but practical tone, calling Q3 “excellent” and emphasizing that the company is building momentum into 2027. He framed the Marlborough plant closure as a difficult but economically rational decision, explaining that production was too small and too costly versus China, while the Tennessee Spill Magic facility shows the opposite case for U.S. manufacturing when the economics and scale work. He also said the company is balancing organic growth and acquisitions, remains selective on deals, and expects First Aid to become increasingly important given that it is about 70% of the business.
Paul Driscoll highlighted the hard numbers behind the quarter: sales of $58 million, gross margin of 45.3%, SG&A of $21.8 million or 37.6% of sales, and net income of $3.4 million or $0.80 per diluted share. He explained that the gross margin improvement reflected a $4 million recognition of the $6 million tariff refund, partially offset by $1.8 million of DMT closure costs, and noted that SG&A was higher mainly due to the addition of My Medic and the advertising required for that direct-to-consumer business. On the balance sheet, net debt increased to $29.7 million from $23.1 million a year ago, while the company generated about $13 million in free cash flow over the last 12 months, after paying $14.5 million for My Medic, $2.4 million in dividends, and $1.6 million for a German product line acquisition.
Analysts pressed on the tariff refund calculation and why Acme chose to close Marlborough while U.S. sales were strong. Management said the refund was calculated by tallying tariffs paid as importer of record and submitting the invoices to IEEPA; on Marlborough, Johnsen said the plant was small, had less than 20 employees, and production had already shifted to China because customers wanted lower-cost product. Another question focused on working capital, with concerns about receivables and inventory; Driscoll said receivables rose because sales were up 18%, while Johnsen said inventory had been intentionally increased by about $8 million-$10 million to protect against shortages and freight inflation, and he expects to convert some of that inventory back into cash during 2027. On promotions and back-to-school strength, Johnsen said the current year compares favorably because last year’s tariff uncertainty delayed promotional activity, and he expects a more normal promotional environment next year if tariffs remain stable.
The call showed broad-based demand, with U.S. sales up 20%, Europe up 7% in local currency, Canada up 12%, and My Medic contributing $4 million in quarterly sales. Management sounded confident that Q4 will be seasonally strong and that 2027 is already seeing booked business in First Aid and continued strength in cutting tools.
Results still benefited materially from a $6 million tariff refund, so the quarter was not purely organic. SG&A rose to 37.6% of sales, net debt increased to $29.7 million, and management acknowledged pressure from shipping costs, freight inflation, and a consumer that may still be stressed by higher rates and other costs. They also said the Marlborough closure will incur a $1 million reserve and that some inventory buildup has a financing cost at an about 6% marginal interest rate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.1%
- Shares Outstanding
- 3.97M
- Float Shares
- 3.14M
of shares held by institutions
84 13F filers
Buy/sell ratio 0.36. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mink Brook Asset Management LLC | 380.81K | ▲ 172 |
| Capital Management Corp /Va | 375.16K | ▼ 98.99K |
| North Star Investment Management Corp. | 247.67K | ▲ 14 |
| Blackrock, Inc. | 188.91K | ▲ 9.15K |
| Dimensional Fund Advisors LP | 182.54K | ▲ 5.41K |
| Vanguard Group Inc | 181.18K | ▲ 584 |
| Vanguard Capital Management LLC | 147.17K | ▲ 2.05K |
| Royce & Associates LP | 146.40K | 0 |
| Renaissance Technologies LLC | 127.21K | ▲ 17.60K |
| Acadian Asset Management LLC | 110.67K | ▲ 32.74K |
| Bard Associates Inc | 106.56K | ▼ 1.64K |
| American Century Companies Inc | 90.55K | ▲ 44.87K |
Held by 113 ETFs
Biggest fund positions in ACU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | MURPHY SUSAN H | other | 100 |
| Nov 16, 26 | MURPHY SUSAN H | other | 100 |
| Nov 9, 26 | BARKER BRIAN | sell | 3,435 |
| Nov 5, 26 | Davidson Rex Lynn | other | 5,000 |
| Nov 5, 26 | Davidson Rex Lynn | other | 4,000 |
| Nov 5, 26 | Davidson Rex Lynn | other | 1,199 |
| Nov 5, 26 | Davidson Rex Lynn | other | 5,000 |
| Nov 5, 26 | Davidson Rex Lynn | other | 4,000 |
| Nov 5, 26 | Davidson Rex Lynn | other | 1,602 |
| Nov 3, 26 | MURPHY SUSAN H | sell | 2,890 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACU coverage
Recent articles, reports, and earnings notes.
No research on ACU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACU report →New Strong Sell Stocks for November 20th
zacks.com · Nov 20
New Strong Sell Stocks for November 17th
zacks.com · Nov 17
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
globenewswire.com · Oct 30
Acme United Q3: Great Performance To Continue, But I Will Not Be Chasing For Now
seekingalpha.com · Oct 28
Acme United: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 27
Acme United Corporation (ACU) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 27
Acme United Corporation. (ACU) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Oct 27
Acme United Reports Third Quarter 2026 Net Sales Increase of 18%
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.